Agenda

Gain a full, straight-talking picture of where fertility policy is moving at both federal and state level and the opportunities presented by changes.

Uncover exactly what new rules mean for how patients find their way to your clinic and get clear on:

• How the new federal employer benefit rule could shift acquisition toward employer relationships over state geography
• What "covered" really means state by state, and where the mandate is weaker than it looks on paper
• What the November 2026 midterms could change about the current coalition backing IVF-friendly federal policy

Format: Closed-door roundtable, 25–35 senior clinic and network leaders, private room.

Providing an aggregate, anonymized view of industry channel mix and drop-off, this session gives clinic owners and network growth leaders a clear read on where fertility patient acquisition is heading and what to do differently as a result.

As social platforms, AI-driven search and benefits-manager channels merge with the traditional OB-GYN referral relationship this session gives clinic and network leaders clarity on:

• Where new patient volume is genuinely coming from in 2026, and how the mix is shifting between networks and independents
• What each acquisition channel is really worth, including benefits-manager and employer-routed volume
• Where in the journey demand is being lost and what's actually moved the needle on reducing that drop-off

Attending clinic owners and network growth leaders need clarity on where the industry is shifting and how to adapt before open discussion begins on:

• Whether the trends match what attendees are seeing in their own markets, or whether their mix is shifting differently
• Where the OB-GYN referral relationship is being displaced fastest, and what's replacing it
• How to prioritise investment across channels given what the data shows about return per patient
• What's worked elsewhere to reduce drop-off at the stage where the room is losing the most demand

Format: Closed-door roundtable, 25–35 senior clinic and network leaders, private room.

Exploring how clinic owners and network leaders are expanding capacity through care-team redesign and smarter technology adoption in the face of physician and embryologist shortages.

Attendees will discuss and gain insight into:

• Where advanced practice provider scope is working, and where operators disagree on the trade-offs
• How to roll a new care model across multiple sites without losing consistency
• What's genuinely deployment-ready versus still development-stage across embryology AI, automation and robotics
• Best practice considerations for technology buying decision

Format: Closed-door roundtable, 25–35 senior clinic and network leaders, private room.

Session Description - Maternity care remains one of the most fragmented journeys in healthcare, and the proliferation of apps, point solutions, and services is making it harder, not easier, for women to find the care that exists. Women cannot find the providers and programs available to them, and providers cannot reach the women who need them.

In this session, Charlotte Williams, midwife and CEO of My Bump My Baby, will introduce My Bump Hub, a maternal ecosystem platform connecting families with providers, organizations, and community resources from preconception through postpartum, including support through loss. She will make the case that organizations across maternal health are not competing with each other; they are competing for the women the system is currently missing.

The modern patient refuses to be passive in her healthcare.

She researches symptoms before appointments, tracks her health through digital tools, takes multiple supplements for preventative care, and arrives at consultations with clearer expectations about the care she wants to access, experience and choose. She is no longer just a patient but an empowered healthcare consumer.

This presentation explores what this shift means for companies seeking to better reach and serve women, innovators building their next solution, employers designing benefits, and physicians caring for increasingly informed patients.

Where are the most promising areas of scientific progress? How is thinking evolving around clinical trials, evidence and inclusion? What will define the next generation of therapies?

Hear from a leading pharmaceutical voice on where the industry is placing its bets. From menopause and reproductive health to cardiometabolic disease and adjacent conditions understand what expanded pharma ambitions mean for women’s health.

Focus on fertility care is increasing, not just within our industry but also culturally, economically, and politically.

The implications for women's healthcare and lives globally are significant. As declining birth rates reshape policy conversations, with countries including China, South Korea, and Japan responding through targeted initiatives, to address falling fertility rates and fertility preservation and reproductive planning moving increasingly into mainstream conversation. This session explores what's driving the gap between demand and access, the role of AI and digital health in diagnostics and treatment, and how women are engaging with fertility treatments in the age of consumerisation of health.

Speakers will examine innovation across drug development, diagnostics, and medical devices, and how employers, policymakers, and healthcare organizations can better support fertility care access. EMD Serono will share how the company is working to expand affordability through pricing initiatives — including Most Favored Nation pricing — and partnerships with the U.S. government, alongside broader efforts to advance access to fertility treatment worldwide.

Attendees will leave with a clearer view of how demographic trends, innovation, and policy are converging to shape fertility care for women globally.